drug-information.ru |
|Imiquimod |
Drugs search, click the first letter of a drug name: | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9 Home ImiquimodPronouncation: (ih-mih-KWIH-mahd)Class: Immunomodulator, Topical Trade Names: Mechanism of ActionPharmacologyUnknown; however, imiquimod induces mRNA encoding cytokines, including interferon-alpha at the treatment site. PharmacokineticsAbsorptionMinimal percutaneous absorption. EliminationLess than 0.9% of topical dose excreted in urine and feces. Indications and UsageTreatment of external genital and perianal warts/condyloma acuminata; treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratosis on the face or scalp in immunocompetent adults; treatment of biopsy-confirmed, primary superficial basal cell carcinoma in immunocompetent adults, with a max tumor diameter of 2 cm located on the trunk, neck, or extremities. ContraindicationsStandard considerations. Dosage and AdministrationExternal Genital WartsAdults and children 12 yr of age and older Topical Apply cream 3 times/wk (eg, Monday, Wednesday, Friday) prior to sleeping hours, and leave on skin for 6 to 10 hr. Remove cream by washing treated area with mild soap and water. Continue treatment until there is total clearance of genital/perianal warts or for a max of 16 wk. Local skin reactions in treatment area are common. Patients should contact health care provider if experiencing any sign or symptom in the treatment area that restricts or prohibits daily activity or makes continued application of the cream difficult. A rest period of several days may be taken if needed because of the patient"s discomfort or severity of the local skin reaction. Actinic KeratosisAdults Topical 2 times/wk (eg, Monday and Thursday) for 16 wk to a defined treatment area on face or scalp (but not both concurrently). Treatment area should be 1 contiguous area of approximately 25 cm 2 . Before applying, the treatment area should be washed with mild soap and water and allowed to dry thoroughly. Apply prior to normal sleeping hours and leave on skin for about 8 hr, after which time cream should be removed by washing the area with mild soap and water. Treatment should continue for the full 16 wk; however, the treatment period should not be extended beyond 16 wk because of missed doses or rest periods. Superficial Basal Cell CarcinomaAdults Topical 5 times/wk (eg, Monday through Friday) for 6 wk to a biopsy-confirmed superficial basal cell carcinoma. The treatment area should include a 1-cm margin of skin around the tumor. Before applying, the treatment area should be washed with mild soap and water and allowed to dry thoroughly. Apply prior to normal sleeping hours and leave on skin for about 8 hr. General Advice
Storage/StabilityStore cream below 77°F. Protect from freezing. Drug InteractionsNone well documented. Laboratory Test InteractionsNone well documented. Adverse ReactionsThe following adverse reactions occurred with an incidence of at least 1% unless otherwise indicated. CardiovascularAtrial fibrillation; chest pain; hypertension. CNSAnxiety; dizziness; fatigue; headache. DermatologicErythema (97%); flaking/scaling/dryness (93%); scabbing crusting (79%); induration (78%); edema (71%); erosion/ulceration (54%); vesicles (29%); weeping/exudates (22%); alopecia; basal cell carcinoma; dermatitis; eczema; hyperkeratosis; rash; skin disorder; squamous carcinoma. EENTEye abnormality; pharyngitis; rhinitis. GIDiarrhea; dyspepsia; gastroesophageal reflux; nausea; vomiting. GenitourinaryUrinary tract disorder. LocalBleeding at target site; burning at remote and target sites; induration at remote and target sites; infection at target site; irritation at remote site; itching at remote and target sites; pain and soreness at target site; papules at target site; procedural site reaction; stinging at target site; tenderness at target site. Metabolic-NutritionalGout; hypercholesterolemia. MusculoskeletalBack pain; myalgia; rigors; skeletal pain. RespiratoryCoughing; sinusitis; upper respiratory tract infection. MiscellaneousAbrasion; allergy aggravated; fever; flu-like symptoms; fungal infection; hernia; herpes simplex; infection; inflicted injury; pain; postoperative pain; viral infection. Precautions
PregnancyCategory C . LactationUndetermined. ChildrenSafety and efficacy in patients with external genital/perianal warts younger than 12 yr of age have not been established. Safety and efficacy in patients with actinic keratosis or superficial basal cell carcinoma younger than 18 yr of age have not been established. ImmunosuppressionSafety and efficacy not established in immunosuppressed patients. SunburnExposure to sunlight or sunlamps should be avoided or minimized. Patient Information
Where can I get more information about Imiquimod ? We recommend to use www.Drugs.com Typical mistypes for Imiquimod umiquimod, jmiquimod, kmiquimod, omiquimod, 9miquimod, 8miquimod, iniquimod, ikiquimod, ijiquimod, imuquimod, imjquimod, imkquimod, imoquimod, im9quimod, im8quimod, imi1uimod, imi2uimod, imiwuimod, imiauimod, imiqyimod, imiqhimod, imiqjimod, imiqiimod, imiq8imod, imiq7imod, imiquumod, imiqujmod, imiqukmod, imiquomod, imiqu9mod, imiqu8mod, imiquinod, imiquikod, imiquijod, imiquimid, imiquimkd, imiquimld, imiquimpd, imiquim0d, imiquim9d, imiquimos, imiquimox, imiquimoc, imiquimof, imiquimor, imiquimoe, miquimod, iiquimod, imquimod, imiuimod, imiqimod, imiqumod, imiquiod, imiquimd, imiquimo, miiquimod, iimquimod, imqiuimod, imiuqimod, imiqiumod, imiqumiod, imiquiomd, imiquimdo, iimiquimod, immiquimod, imiiquimod, imiqquimod, imiquuimod, imiquiimod, imiquimmod, imiquimood, imiquimodd, etc.
|